Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03618654 · ClinicalTrials.gov registry record · Early Phase 1
Durvalumab With or Without Metformin in Treating Participants With Head and Neck Squamous Cell Carcinoma
A Early Phase 1 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 38
- Enrollment target
NCT03618654 is a Early Phase 1 study that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University. The registered enrollment target is 38 participants.
The verdict
NCT03618654, a Early Phase 1 study, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 38 participants
- Enrollment target
Study Summary
This pilot phase I trial studies how well durvalumab given with or without metformin works in treating participants with head and neck squamous cell carcinoma. Monoclonal antibodies, such as durvalumab, may interfere with the ability of tumor cells to grow and spread. Metformin, a drug typically used for the treatment of diabetes, may help to reduce the metabolic activity of cancer cells and of surrounding supportive tissues. It is not yet known whether giving durvalumab with or without metformin may work better in treating participants with head and neck squamous carcinoma.
Interventions
- BIOLOGICAL Durvalumab
- DRUG Metformin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2018-11-01 |
| Est. Completion | 2022-12-07 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03618654
The ClinicalTrials.gov registry entry for NCT03618654 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, which has 138 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Durvalumab is the first listed.
NCT03618654 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03618654 about?
NCT03618654 is a clinical study titled "Durvalumab With or Without Metformin in Treating Participants With Head and Neck Squamous Cell Carcinoma". This pilot phase I trial studies how well durvalumab given with or without metformin works in treating participants with head and neck squamous cell carcinoma. Monoclonal antibodies, such as durvalumab, may interfere with the ability of tumor cells to grow and spread. Metformin, a drug typically use...
What is the current status of trial NCT03618654?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 38 participants. The study started on 2018-11-01. Estimated completion is 2022-12-07.
What interventions are being tested in trial NCT03618654?
The interventions under investigation include: Durvalumab (BIOLOGICAL), Metformin (DRUG).
Who is sponsoring clinical trial NCT03618654?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, which has 138 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.